8:00 am Registration Opens

8:45 am Chair’s Opening Remarks – Where Are We & Where Are We Going? Overview of Recent Exciting NSCLC Abstracts

  • Eric Murphy CEO, Chief Scientific Officer & Co-Founder, Alterome Therapeutics

Emerging Approaches to Targeting NSCLC

9:00 am Progress in Newly Diagnosed Actionable Mutations

  • Rob Kania Senior Vice President of Drug Discovery, Kinnate

Synopsis

• Rationale & updates for novel TKIs
• Discussing the safety and efficacy of novel TKIs that target the eight molecular subtypes/currently actionable alterations
• Latest data & future directions

9:30 am KRAS G12C Development: New Opportunities…

  • Jill Hallin Senior Principal Scientist, Mirati Therapeutics

Synopsis

  • Exploring adagrasib preclinical combinations
  • Looking into patient combos, brain met data and  more

10:00 am Speed Networking

11:00 am Morning Refreshments

Drug Development Progress in Late-Line Non-Small Cell Lung Cancer

12:00 pm Investigating Safety & Efficacy of Novel Immunotherapies in Clinical Investigation in NSCLC

Synopsis

  • Understanding the translational timeline, patient population and
    combination rationale
  • Exploring the latest clinical data, challenges and future directions into earlier lines

12:30 pm Panel Discussion: Exploring the Strategic Challenges of Moving Forward a Drug You Want to Combine with PD-1 in Chemo+PD-1 Progressors

  • Phillip Dennis Vice President, Lung Cancer & Oncology Development, Sanofi
  • Stephen Horrigan Chief Scientific Officer, Iterion Therapeutics
  • Emmett Schmidt Vice President, Lead External Collaborations Project Team Global Clinical Development, Merck & Co
  • Roger Waltzman Chief Medical Officer, Molecular Templates

Synopsis

  • Understanding the different current comparators and benchmarks
  • Exploring the differences in PD-1 naïve and PD-1 progressors
  • Dissecting why sometimes beating chemo and PD-1 could be an unachievable bar
  • Discussing whether with late-line in-effectivity, how you know it won’t work in early line?
  • Considering the health authorities’ standards on the matter

Understanding PD-1 Resistance & Improved Dissection of Patient Populations in Later-Line NSCLC

2:30 pm Exploring MT-6402, a Novel Engineered Toxin Body Targeting PD-L1—Interim Data of a Dose Escalation Trial in Patients with Relapsed/Refractory PD-L1-Expressing Solid Tumors

2:30 pm Exploring BLU-945 in EGFR-Mutated NSCLC

  • Faris Albayya Translational Medicine Scientist, Blueprint Medicines

Synopsis

  • Exploring the latest translational research
  • Discussing potential combinations and treatment line
  • Latest data and future directions

3:00 pm Poster Session

Optimizing Sequencing & Combination Rationale in Later Lines of Therapy

3:30 pm Informed By The Tumor: The Power of a Personalized ctDNA Assay For MRD Detection & Monitoring in NSCLC

Synopsis

  • Latest clinical data from 2022 publications and presentations
  • Advantages of a personalized, tumor-informed ctDNA assay for molecular residual
    disease detection
  • Applications of Signatera in clinical trial design to maximize trial success, and
    accelerate time to data readout

4:00 pm Advancements in ADCs for later-line NSCLC

  • Phillip Dennis Vice President, Lung Cancer & Oncology Development, Sanofi

Synopsis

  • Exploring the latest translational research
  • Discussing potential combinations and treatment line
  • Latest data and future directions

4:30 pm Synergy is a 4 Letter Word: Lessons of Independent Action as an Explanation for the Efficacy of Cancer Clinical Combination Therapies

  • Emmett Schmidt Vice President, Lead External Collaborations Project Team Global Clinical Development, Merck & Co

Synopsis

– Immuno oncology drugs are failing at an unprecedented rate, perhaps because too much reliance has been placed on pre-clinical thinking about synergy
– Based on the mathematics of Independent Action, synergy has not been seen in any immuno oncology registration trials to date
– To progress development of combinations of ADC and PD-1 immune checkpoint inhibitors, the field must adapt more rigorous mathematic thinking about combination results

5:00 pm Targeted Therapies in Late Lines of NSCLC: Sequencing & Combination Regimens

Synopsis

  • Relevance of sequencing drugs to address resistance
  • Combination regimens to improve efficacy
  • Addressing mechanisms of resistance to targeted therapies

5:30 pm Chair’s Closing Remarks & End of Day 1